Badr University
Cairo, 002, Egypt
NCT Number: NCT05614167
Muscle strength can be defined as the ability of skeletal muscle to develop force for the purpose of providing stability and mobility within the musculoskeletal system, so that functional movement can take place.
Looking for future studies?
Notify Me6 year–12 year
All sexes
Observational
Cairo, 002, Egypt
Cerebral palsy describes a group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fatal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, cognition, communication, perception, and/or behaviour, and/or by a seizure disorder
The development and changes in motor function, both natural and with therapy, can be assessed using the Gross Motor Function Measure (GMFM) created for children with CP
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
Time frame: 3 months
standing and walking domain
Time frame: 3 months
a handheld dynamometer
Badr University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02918890
Behavior, Brain Damage, Chronic
New York, United States
View Trial DetailsNCT05134272
Brain Damage, Chronic, Brain Diseases
Maple Grove, Minnesota, United States
View Trial DetailsNCT00632528
Brain Damage, Chronic, Brain Diseases
Paris, France
View Trial DetailsNCT04259814
Behavior, Brain Damage, Chronic
Chicago, Illinois, United States
View Trial Details